الفهرس 
ABSTRACTOnly 14 pages are availabe for public view
 |  | from | 177 |  |  |
| | | from | 177 | | |
Abstract
Until 2011, the American Association for the Study of Liver Disease guidelines recommended dual therapy, a combination of pegylated interferon and ribavirin for 24 to 48 weeks, to treat chronic HCV infection. This treatment regimen produced low sustained virologic response, had a number of restrictions and a number of side effects. With the emergence of Direct Acting Antiviral drugs, a new hope for the treatment of HCV was proposed as they promised higher SVR, less side effects and shorter duration of treatment.
The current study is a longitudinal comparative study that aims at comparing the traditional dual regimen of pegylated interferon and ribavirin versus the triple regimen of pegylated interferon, ribavirin and sofosbuvir; and with the merge of various DAA, the study was extended to include other nouvel treatment regimens. Two more groups were included, one regimen containing SOF plus RBV alone; and another containing SOF and DCV with or without RBV.
The study was conducted on 200 treatment naïve Egyptian patients who were infected with HCV. Patients were selected from HCV patients that attended the national virology center of beni-sueif. These patients were divided into 4 groups of 50:
group A patients were given pegylated interferon (pegasys) and ribavirin for 24 weeks.
group B patients were given pegylated interferon (pegasys), ribavirin and sofosbuvir for 12 weeks.
group C patients were given sofosbuvir and ribavirin for 12 weeks.
group D patients were given sofosbuvir and daclatasvir for 12 weeks.
In comparing the 4 groups, it was found that the group with the highest SVR12 was group D patients who have had received SOF+DCV with or without Ribavirin who achieved a SVR12 of 96% followed by group B (IFN+RBV) who achieved a SVR12 OF 72%, then group C (SOF+RBV) followed by group A (SOF+DCV with or without RBV) with SVR12 OF 64% and 58% respectively.
The most commonly associated side effects in the 4 groups were mainly headache followed by fatigue with both being higher in groups receiving interferon (groups A and B) with 12 patients in group A and 9 patients in group B experiencing headache while 4 patients in group C and 3 patients in group D had headache. In the meantime, fatigue was found in 9 patients in group A and 8 patients in group B; and to lesser extent 5 patients in group C and 2 patients in group D.
It was found that a total of 9 patients stopped treatment. In group A, 5 patients stopped treatment because they developed anaemia (<7g/dl) and in group B, 4 patients stopped treatment; 1 could not tolerate the treatment (severe nausea and vomiting) and 3 developed anaemia (<7 g/dl). While patients in groups C and D all tolerated treatment.
The most prevalent co-morbidities in patients included in the study were diabetes followed by hypertension with diabetes in groups C and D having the highest number of patients among the 4 groups with 10 patients in group C and 8 patients in group D, versus 3 in group A and 7 in group B; hypertension was having the highest number of patients in groups C and B with 9 patients in group C and 5 patients in group D, versus 4 patients in group D and 1 patient in group A.